AI-generated analysis. Always verify with the original filing.
Bonus Biogroup Ltd., an Israeli clinical-stage biotechnology company founded in 1981 and listed on the Tel Aviv Stock Exchange since 1993, develops next-generation tissue engineering and cell therapy products. Its lead candidates are BonoFill, a personalized autologous bone graft for bone regeneration in maxillofacial and orthopedic defects, with Phase II completed for maxillofacial (2024) and ongoing for limb bones (enrollment completion expected 2026), and MesenCure, an allogeneic MSC therapy for respiratory distress including ARDS, with Phase II completed in 2022 for COVID-19 pneumonia and FDA IND clearance for Phase III in February 2025 (initiation planned 2026). The company reports recurring losses, with net comprehensive loss of NIS 27.8 million ($8.3 million) for 2024 and accumulated deficit of NIS 350.3 million ($103.9 million) as of June 30, 2025, alongside cash of NIS 1.2 million ($355,000). It is offering 3,000,000 ADSs (each representing 30 ordinary shares) at $4.00-$6.00 per ADS, targeting $12.7-$14.8 million in net proceeds (midpoint $5.00), primarily for Phase III trials of MesenCure ($4.2-$4.9 million) and BonoFill ($1.2-$1.9 million), preclinical/early clinical work ($4.8-$5.6 million), and working capital. As an emerging growth company and foreign private issuer, Bonus seeks Nasdaq listing under 'BONS' to fund clinical advancement toward U.S. approvals, leveraging proprietary MSC technology and cGMP facilities amid substantial going concern doubts due to cash burn.
Offering Amount
$5.1M
Shares Offered
1,271,425,311
Price Range
$4.00 – $6.00
Issuer Type
Shares Offered
3,000,000
Offering Amount
$12.7 million (or $14.8 million if underwriter exercises full option)
Price Range
$4.00 and $6.00 per ADS
Share Type
American Depositary Shares (each representing 30 ordinary shares)
Exchange
Nasdaq Capital Market
Ticker
BONS
Use of Proceeds: $4.8-$5.6M preclinical/early clinical; $4.2-$4.9M MesenCure Phase III; $1.2-$1.9M BonoFill Phase III; remainder working capital.
Clinical-stage biotechnology company focused on developing next-generation therapies in tissue engineering and cell therapy, with lead candidates BonoFill (autologous bone graft) and MesenCure (allogeneic cell therapy for inflammation and tissue damage).